Scientific Reports (Dec 2022)
Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria
- Chinedu Ugwu,
- Testimony Olumade,
- Ebenezer Nwakpakpa,
- Venatius Onyia,
- Elizabeth Odeh,
- Rosemary Ogonna Duruiheoma,
- Chiedozie K. Ojide,
- Matthew Afam Eke,
- Ifeanyi Emmanuel Nwafor,
- Nneka Chika-Igwenyi,
- Augustine M. Abu,
- Benedict Azuogu,
- Nnennaya Ajayi,
- Emeka Ogah,
- Oluwafemi Ayodeji,
- Chukwuyem Abejegah,
- Nelson Adedosu,
- Nicholas Oyejide,
- Sylvester Abah,
- Abiola Omidele,
- Winifred Ingbian,
- Emmanuel Osoba,
- Philomena Eromon,
- Paul Oluniyi,
- Olusola Ogunsanya,
- Anise Happi,
- Patricia Otuh,
- Angalee Nadesalingam,
- George Carnell,
- Nina Krause,
- Ernest Aguinam,
- Rebecca Kinsley,
- Daniel Matthew L. Storisteanu,
- Paul Tonks,
- Diana Nelson,
- Carley McAlister,
- Matthew Boisen,
- Robert Garry,
- Edward Wright,
- Nigel Temperton,
- Simon Frost,
- Jonathan Luke Heeney,
- Christian Happi
Affiliations
- Chinedu Ugwu
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Testimony Olumade
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Ebenezer Nwakpakpa
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Venatius Onyia
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Elizabeth Odeh
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Rosemary Ogonna Duruiheoma
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Chiedozie K. Ojide
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Matthew Afam Eke
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Ifeanyi Emmanuel Nwafor
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Nneka Chika-Igwenyi
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Augustine M. Abu
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Benedict Azuogu
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Nnennaya Ajayi
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Emeka Ogah
- Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)
- Oluwafemi Ayodeji
- Federal Medical Centre Owo
- Chukwuyem Abejegah
- Federal Medical Centre Owo
- Nelson Adedosu
- Federal Medical Centre Owo
- Nicholas Oyejide
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Sylvester Abah
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Abiola Omidele
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Winifred Ingbian
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Emmanuel Osoba
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Philomena Eromon
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Paul Oluniyi
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Olusola Ogunsanya
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Anise Happi
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- Patricia Otuh
- Michael Okpara University of Agriculture
- Angalee Nadesalingam
- Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge
- George Carnell
- Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge
- Nina Krause
- Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge
- Ernest Aguinam
- Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge
- Rebecca Kinsley
- Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge
- Daniel Matthew L. Storisteanu
- Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge
- Paul Tonks
- Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge
- Diana Nelson
- Zalgen Labs, LCC
- Carley McAlister
- Zalgen Labs, LCC
- Matthew Boisen
- Zalgen Labs, LCC
- Robert Garry
- Department of Microbiology and Immunology, School of Medicine, Tulane University
- Edward Wright
- School of Life Sciences, University of Sussex
- Nigel Temperton
- Medway School of Pharmacy, The Universities of Greenwich and Kent Medway
- Simon Frost
- London School of Hygiene & Tropical Medicine
- Jonathan Luke Heeney
- Michael Okpara University of Agriculture
- Christian Happi
- The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University Nigeria
- DOI
- https://doi.org/10.1038/s41598-022-26045-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 9
Abstract
Abstract Elucidating the adaptive immune characteristics of natural protection to Lassa fever (LF) is vital in designing and selecting optimal vaccine candidates. With rejuvenated interest in LF and a call for accelerated research on the Lassa virus (LASV) vaccine, there is a need to define the correlates of natural protective immune responses to LF. Here, we describe cellular and antibody immune responses present in survivors of LF (N = 370) and their exposed contacts (N = 170) in a LASV endemic region in Nigeria. Interestingly, our data showed comparable T cell and binding antibody responses from both survivors and their contacts, while neutralizing antibody responses were primarily seen in the LF survivors and not their contacts. Neutralizing antibody responses were found to be cross-reactive against all five lineages of LASV with a strong bias to Lineage II, the prevalent strain in southern Nigeria. We demonstrated that both T cell and antibody responses were not detectable in peripheral blood after a decade in LF survivors. Notably LF survivors maintained high levels of detectable binding antibody response for six months while their contacts did not. Lastly, as potential vaccine targets, we identified the regions of the LASV Glycoprotein (GP) and Nucleoprotein (NP) that induced the broadest peptide-specific T cell responses. Taken together this data informs immunological readouts and potential benchmarks for clinical trials evaluating LASV vaccine candidates.